Data gathered: December 21
AI Stock Analysis - Tarsus Pharmaceuticals (TARS)
Analysis generated July 21, 2024. Powered by Chat GPT.
Tarsus Pharmaceuticals is a biopharmaceutical company concentrated on the development and commercialization of therapeutic treatments in the field of eye care. The company is focused on innovative solutions and has shown a strong commitment to research and development, which is reflected in the significant growth rates seen in their financial reports. Their portfolio includes products that are in various stages of clinical trials, and they are continuously looking to expand their market reach and product line.
Stock Alerts - Tarsus Pharmaceuticals (TARS)
 |
Tarsus Pharmaceuticals | December 18 Price is up by 6.1% in the last 24h. |
|
Tarsus Pharmaceuticals | December 11 Price is up by 5.6% in the last 24h. |
|
Tarsus Pharmaceuticals | December 2 Price is down by -5.1% in the last 24h. |
|
Tarsus Pharmaceuticals | November 26 Price is up by 5.3% in the last 24h. |
Alternative Data for Tarsus Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 15 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 57,000 | Sign up | Sign up | Sign up |
| Employee Rating | 92 | Sign up | Sign up | Sign up |
| Google Trends | 10 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 8 | Sign up | Sign up | Sign up |
| Facebook Followers | 454 | Sign up | Sign up | Sign up |
| Instagram Followers | 1,089 | Sign up | Sign up | Sign up |
| Reddit Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 673 | Sign up | Sign up | Sign up |
| Twitter Followers | 599 | Sign up | Sign up | Sign up |
| Twitter Mentions | 18 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 100 | Sign up | Sign up | Sign up |
| Linkedin Employees | 322 | Sign up | Sign up | Sign up |
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States.
| Price | $52.91 |
| Target Price | Sign up |
| Volume | 737,570 |
| Market Cap | $1.99B |
| Year Range | $21.54 - $53.26 |
| Dividend Yield | 0% |
| Analyst Rating | 86% buy |
| Industry | Biotechnology |
In the news
 |
Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap Down – What’s Next?December 14 - ETF Daily News |
 |
Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 PicksDecember 14 - SeekingAlpha |
|
23,199 Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Bought by Verition Fund Management LLCDecember 10 - ETF Daily News |
 |
Tarsus Pharmaceuticals: Early Rollout Exceeding ExpectationsDecember 9 - SeekingAlpha |
 |
Wall Street Analysts Think Tarsus Pharmaceuticals (TARS) Could Surge 26.98%: Read This Before Placing a BetDecember 3 - Yahoo |
|
Brokerages Set Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) PT at $54.20December 1 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 48M | 58M | -9.9M | -23M | -25M | -0.610 |
| Q2 '24 | 41M | 59M | -18M | -33M | -33M | -0.880 |
| Q1 '24 | 28M | 52M | -24M | -36M | -38M | -1.010 |
| Q4 '23 | 13M | 43M | -30M | -42M | -41M | -1.310 |
| Q3 '23 | 1.9M | 30M | -28M | -39M | -39M | -1.280 |
Insider Transactions View All
| LINK WILLIAM J PHD filed to sell 5,021 shares at $26. August 14 '24 |
| Farrow Jeffrey S filed to sell 18,136 shares at $27.5. June 20 '24 |
| Neervannan Seshadri filed to sell 64,767 shares at $30.6. March 19 '24 |
| Whitfield Dianne C. filed to sell 34,181 shares at $30.6. March 19 '24 |
Similar companies
Read more about Tarsus Pharmaceuticals (TARS) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Tarsus Pharmaceuticals?
The Market Cap of Tarsus Pharmaceuticals is $1.99B.
What is the current stock price of Tarsus Pharmaceuticals?
Currently, the price of one share of Tarsus Pharmaceuticals stock is $52.91.
How can I analyze the TARS stock price chart for investment decisions?
The TARS stock price chart above provides a comprehensive visual representation of Tarsus Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Tarsus Pharmaceuticals shares. Our platform offers an up-to-date TARS stock price chart, along with technical data analysis and alternative data insights.
Does TARS offer dividends to its shareholders?
As of our latest update, Tarsus Pharmaceuticals (TARS) does not offer dividends to its shareholders. Investors interested in Tarsus Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Tarsus Pharmaceuticals?
Some of the similar stocks of Tarsus Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.